EN DE

EuroEyes International Eye Clinic Ltd (1846) Fair Value & Analysis

Healthcare · HK · Market cap HK$780M

EI EuroEyes International Eye Clinic Ltd 1846 · HK
PriceHK$2.87
Fair ValueHK$3.75
Upside+30.7%
Quality66/100
Watch EuroEyes International Eye Clinic Ltd for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 6.8% net margin
Low debt · generates free cash flow
1.87% dividend yield
Ranks above peers (11/13)
Narrow moat 40/100
Evidence: High Range HK$2.81 – HK$4.69 Share as image

Fair value as of: Aug 17, 2026

From 26 valuation models · updated today

Share price +24.8% over the past month.

A solid business, screening 31% undervalued on our models.

What matters now

  • Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
  • Our model range runs from HK$2.81 (bear) to HK$4.69 (bull), base HK$3.75. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 66/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$13.06 HK$2.30 Fair Value HK$3.75 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.

How to read this chart

60‑month range HK$2.30 – HK$13.06 · fair‑value band HK$2.81 – HK$4.69 · the HK$2.87 price screens below the HK$3.75 fair value. Dashed = 300-day average. As of Aug 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

EuroEyes International Eye Clinic Ltd (1846) currently trades at HK$2.87, while our model-based Fair Value estimate is HK$3.75, implying the stock looks roughly 30.7% undervalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, EuroEyes International Eye Clinic Ltd generated revenue of HK$796M at a net margin of 6.8%. Revenue grew 20.6% year over year. It earns a return on equity of 4.7%. The balance sheet holds a net cash position of HK$287M. Fundamentals as of Aug 17, 2026

Our scenario range runs from HK$2.81 (bear case) to HK$4.69 (bull case); at HK$2.87, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 16% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 31%, 1846 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$6.93 HK$9.62 HK$13.42 80
Residual Income HK$2.77 HK$2.71 HK$2.32 76
Rev-Margin DCF HK$5.97 HK$8.30 HK$11.27 74
All 26 models by family
DCF Models
FCF DCF HK$6.99 HK$10.01 HK$14.53 38
Owner Earnings HK$6.61 HK$9.40 HK$13.56 31
5Y Revenue Exit HK$5.97 HK$8.31 HK$11.40 39
5Y EBITDA Exit HK$8.49 HK$13.43 HK$19.57 41
5Y P/E Exit HK$5.58 HK$7.53 HK$9.66 38
10Y Revenue Exit HK$6.22 HK$8.43 HK$11.64 36
10Y EBITDA Exit HK$7.83 HK$11.83 HK$17.79 37
10Y P/E Exit HK$6.07 HK$7.91 HK$10.34 35
Earnings-Based
Graham-Dodd HK$1.16 HK$5.09 HK$6.96 54
Lynch FV HK$1.31 HK$1.88 HK$2.44 50
PEG = 1.0 HK$1.31 HK$1.88 HK$2.44 46
EPV HK$3.90 HK$4.14 HK$4.33 59
Dividend Discount
Gordon GGM HK$0.5000 HK$0.8900 HK$1.23 70
DDM Multi-Stage HK$0.5000 HK$0.8200 HK$0.9500 61
Multiples
P/E Multiple HK$2.81 HK$3.75 HK$4.69 63
P/S Multiple HK$2.17 HK$2.90 HK$3.62 58
P/B Multiple HK$2.17 HK$2.90 HK$3.62 55
EV/EBIT HK$6.75 HK$8.28 HK$9.80 53
EV/EBITDA HK$10.14 HK$12.80 HK$15.45 54
EV/Revenue HK$5.45 HK$6.84 HK$8.24 43
Asset-Based
NCAV (Graham) HK$1.96 HK$2.62 HK$3.91 50
Growth DCF
Growth DCF HK$6.93 HK$9.62 HK$13.42 80
Rev-Margin DCF HK$5.97 HK$8.30 HK$11.27 74
Economic Profit
Residual Income HK$2.77 HK$2.71 HK$2.32 76
ROIC Compounder HK$3.90 HK$4.32 HK$4.87 72
Growth Earnings
Growth-Adj P/E HK$2.23 HK$3.18 HK$4.14 68

Widest divergence: DCF Models (HK$8.43) versus Dividend Discount (HK$0.8200). Highest evidence: Growth DCF (80).

Notify me when 1846 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$796M
Revenue growth (YoY) +20.6%
Net margin 6.8%
Return on equity 4.7%
Free cash flow HK$148M FY2025
P/E ratio 14.4 as of Jul 2, 2026
More key figures
Operating margin 11.7%
EPS (TTM) HK$0.1200
Dividend yield 1.9%
EPS growth (YoY) -56.7%
Net cash HK$287M FY2025

Figures from reported company fundamentals · as of Aug 17, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 66 · Market factors (momentum, volatility) 46

Profitability 30
Margins and returns on capital today
Quality Growth 45
Are margins and returns improving?
Cashflow 83
Earnings quality: real cash, not paper profit
Fin. Strength 79
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 70
Calm price path (market factor)
Momentum 35
Price trend over the last 3–12 months (market factor)
52W Momentum 36
Distance to the 52-week high (market factor)
Net Issuance 98
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

EuroEyes International Eye Clinic Limited provides vision correction services in Germany, the People's Republic of China, Denmark, the United Kingdom, and Switzerland.

Full company description

EuroEyes International Eye Clinic Limited provides vision correction services in Germany, the People's Republic of China, Denmark, the United Kingdom, and Switzerland. The company offers laser eye surgery in various options, including SMILE Pro, Femto-Lasik, PRK, and Lasek; refractive laser surgery, such as ReLEx SMILE, Femto LASIK, and Presbyond; phakic lens surgery; lens exchange surgery, comprising monofocal and trifocal lens exchange surgery; and PRK/LASEK and ICRS implantation services. It also sells pharmaceutical products; rental of ophthalmic equipment and operating spaces; and provides training services. In addition, the company is involved in the operation of consultation centers and/or clinics for eye treatment; and trading of eye clinic equipment and lenses. EuroEyes International Eye Clinic Limited was founded in 1993 and is headquartered in Hamburg, Germany.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

EuroEyes International Eye Clinic Ltd reported revenue of HK$796M in FY2025 versus HK$633M in FY2021, a compound +5.9%/yr. Reported net income was HK$54.5M in FY2025, compounding −20.1%/yr from FY2021.

Growth Quality 83/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$796M
Latest YoY
+11.2%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+9.3%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+10.9%
Avg. growth/yr (9Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.8%
Revenue +5.9%/yr
FY21 HK$633M
FY22 HK$610M
FY23 HK$714M
FY24 HK$716M
FY25 HK$796M
Net income −20.1%/yr
FY21 HK$134M
FY22 HK$89.5M
FY23 HK$131M
FY24 HK$82.3M
FY25 HK$54.5M

Watch 1846: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "EuroEyes International Eye Clinic Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1846

Peer Group

Medical Care Facilities · 266 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 66 · Top 25%
Fair Value upside +31% · Above median
Return on equity (TTM) 5% · Below median
Return on assets 4% · Above median
Net margin (TTM) 7% · Above median
Operating margin (TTM) 12% · Above median
Revenue growth 21% · Top 25%
Dividend yield (TTM) 1.9% · Below median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 14.4× · Cheaper than median
P/B 0.62× · Cheaper than 75% of peers
P/S (TTM) 0.98× · Cheaper than median
P/FCF 0.7× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 74 · sector 26
FUTURE 100 · sector 23
PAST 19 · sector 29
HEALTH 100 · sector 90
DIVIDEND 37 · sector 41

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).

Compare EuroEyes International Eye Clinic Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is EuroEyes International Eye Clinic Ltd (1846) overvalued or undervalued?
As of Aug 17, 2026, our model estimates a fair value of HK$3.75 versus a price of HK$2.87, about +31% (undervalued).
What is the fair value of 1846?
Our model-based fair value for EuroEyes International Eye Clinic Ltd is HK$3.75 (as of Aug 17, 2026), built from audited fundamentals. The current price is HK$2.87.
What is the quality score of 1846?
EuroEyes International Eye Clinic Ltd has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of EuroEyes International Eye Clinic Ltd (1846)?
EuroEyes International Eye Clinic Ltd reported trailing-twelve-month revenue of about HK$796M (latest available figure, as of Aug 17, 2026).
What is the net profit margin of 1846?
The net profit margin of EuroEyes International Eye Clinic Ltd is about 6.8%, meaning it keeps roughly 6.8% of revenue as net income. Based on the latest reported figures.
Does EuroEyes International Eye Clinic Ltd pay a dividend?
EuroEyes International Eye Clinic Ltd currently shows a dividend yield of about 1.87% relative to its recent price (as of Aug 17, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track EuroEyes International Eye Clinic Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.